J&J forms 'innovation centres' in global biotech hubs to access emerging tech

Johnson & Johnson's new regional "innovation centres" will expand on the company's success with the US Janssen Labs project that opened earlier this year in San Diego to assist life science startups and connect the pharmaceutical company to promising new therapeutics, medical devices and consumer healthcare products (scripintelligence.com, 20 January 2012).

Johnson & Johnson's new regional "innovation centres" will expand on the company's success with the US Janssen Labs project that opened earlier this year in San Diego to assist life science startups and connect the pharmaceutical company to promising new therapeutics, medical devices and consumer healthcare products (scripintelligence.com, 20 January 2012).

J&J announced on 18 September that it will establish four innovation centres in California (in San Francisco with a San Diego office), Boston, London, UK (covering Europe) and China...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By 

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

 
• By 

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.